Clinical Trials
9 trialsNCT03480360 2026-02-19
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
Phase 3 Active not recruiting
NCT03959241 2024-04-04
1703/1801
Medical College of Wisconsin
Phase 3 Completed
NCT01951885 2023-09-11
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Case Comprehensive Cancer Center
Phase 3 Completed
NCT04095858 2023-02-08
CATHY
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT00406393 2023-01-04
BMT CTN 0402
Medical College of Wisconsin
Phase 3 Completed
NCT01471444 2021-12-16
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00382109 2019-08-07
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
Children's Oncology Group
Phase 3 Completed
NCT00928018 2019-02-01
Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
Dana-Farber Cancer Institute
Phase 3 Completed
NCT00322101 2014-10-31
Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
Fred Hutchinson Cancer Center
Phase 3 Completed